HIV-associated lymphoma in the era of combination antiretroviral therapy: Shifting the immunological landscape

Pathogens and Disease

Volumn 73, Issue 7, 2015, Pages

  Carroll, Virginia ^a   Garzino Demo, Alfredo ^a,b  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PADOVA   (Italy)

Author keywords

Antiretroviral drugs; Chronic infection; HIV 1; Immune activation; Lymphomagenesis; Virus

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIRETROVIRUS AGENT;

B LYMPHOCYTE ACTIVATION; CANCER MORTALITY; CANCER RISK; CARCINOGENESIS; CD4 LYMPHOCYTE COUNT; HELPER CELL; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HODGKIN DISEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOMA; LYMPHOPOIESIS; NATURAL KILLER CELL; NONHODGKIN LYMPHOMA; NONHUMAN; PRIORITY JOURNAL; RISK REDUCTION; SHORT SURVEY; TREATMENT RESPONSE; TUMOR MICROENVIRONMENT; COMPLICATION; HIV INFECTIONS; IMMUNOLOGY; LYMPHOMA, AIDS-RELATED;

ANTI-RETROVIRAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; HIV INFECTIONS; HUMANS; LYMPHOMA, AIDS-RELATED;

EID: 85002057631     PISSN: None     EISSN: 2049632X     Source Type: Journal    
DOI: 10.1093/femspd/ftv044     Document Type: Short Survey

References (74)

1. Basta D, Latinovic O, Lafferty MK. Angiogenic, lymphangiogenic and adipogenic effects of HIV-1 Matrix protein p17, 2015, submitted.
2. Bohlius J, Schmidlin K, Costagliola D, et al. Prognosis of HIVassociated non-Hodgkin lymphoma in patients starting combination antiretroviral therapy. AIDS 2009;23:2029-37.
3. Buckner CM, Moir S, Ho J, et al. Characterization of plasmablasts in the blood of HIV-infected viremic individuals: evidence for nonspecific immune activation. J Virol 2013;87:5800-11.
4. Caccuri F, Giagulli C, Bugatti A, et al. HIV-1 matrix protein p17 promotes angiogenesis via chemokine receptors CXCR1 and CXCR2. P Natl Acad Sci USA 2012;109:14580-5.
5. Caccuri F, Rueckert C, Giagulli C, et al. HIV-1 matrix protein p17 promotes lymphangiogenesis and activates the endothelin-1/endothelin B receptor axis. Arterioscl Throm Vas 2014;34:846-56.
6. Capello D, Scandurra M, Poretti G, et al. Genome wide DNAprofiling of HIV-related B-cell lymphomas. Brit J Haematol 2010;148:245-55.
7. Carbone A. AIDS-related non-Hodgkin's lymphomas: from pathology and molecular pathogenesis to treatment. Human Pathol 2002;33:392-404.
8. Carbone A, Cesarman E, Spina M, et al. HIV-associated lymphomas and gamma-herpesviruses. Blood 2009;113:1213-24.
9. Carter CC, Onafuwa-Nuga A, McNamara LA, et al. HIV-1 infects multipotent progenitor cells causing cell death and establishing latent cellular reservoirs. Nat Med 2010;16:446-51.
10. Chao C, Silverberg MJ, Martínez-Maza O, et al. Epstein-Barr virus infection and expression of B-cell oncogenic markers in HIV-related diffuse large B-cell Lymphoma. Clin Cancer Res 2012;18:4702-12.
11. Chao C, Xu L, Abrams D, et al. Survival of non-Hodgkin lymphoma patients with and without HIV infection in the era of combined antiretroviral therapy. AIDS 2010;24:1765-70.
12. Contreras-Galindo R, Kaplan MH, Leissner P, et al. Human endogenous retrovirus K (HML-2) elements in the plasma of people with lymphoma and breast cancer. J Virol 2008;82:9329-36.
13. Corbeau P, Reynes J. Immune reconstitution under antiretroviral therapy: the new challenge in HIV-1 infection. Blood 2011;117:5582-90.
14. Crotty S. Follicular helper CD4 T cells (TFH). Annu Rev Immunol 2011;29:621-63.
15. Cubas RA, Mudd JC, Savoye AL, et al. Inadequate T follicular cell help impairs B cell immunity during HIV infection. Nat Med 2013;19:494-9.
16. Curreli S, Krishnan S, Reitz M, et al. B cell lymphoma in HIV transgenic mice. Retrovirology 2013;10:92.
17. D'Andrea G, Brisdelli F, Bozzi A. AZT: an old drug with new perspectives. Curr Clin Pharmacol 2008;3:20-37.
18. De, Francesco MA, Baronio M, Fiorentini S, et al. HIV-1 matrix protein p17 increases the production of proinflammatory cytokines and counteracts IL-4 activity by binding to a cellular receptor. P Natl Acad Sci USA 2002;99:9972-7.
19. Diamond C, Taylor TH, Im T, et al. Presentation and outcomes of systemic non-Hodgkin's lymphoma: a comparison between patients with acquired immunodeficiency syndrome (AIDS) treated with highly active antiretroviral therapy and patients without AIDS. Leukemia Lymphoma 2006;47: 1822-9.
20. Dolcetti R, Dal Col J, Martorelli D, et al. Interplay among viral antigens, cellular pathways and tumormicroenvironment in the pathogenesis of EBV-driven lymphomas. Semin Cancer Biol 2013;23:441-56.
21. Dunleavy K,WilsonWH. How I treat HIV-associated lymphoma. Blood 2012;119:3245-55.
22. Durand CM, Ghiaur G, Siliciano JD, et al. HIV-1 DNA is detected in bone marrow populations containing CD4+ T cells but is not found in purified CD34 +hematopoietic progenitor cells in most patients on antiretroviral therapy. J Infect Dis 2012;205:1014-8.
23. Fiorentini S, Marini E, Caracciolo S, et al. Functions of the HIV-1 matrix protein p17. New Microbiol 2006;29:1-10.
24. Forthal DN, Landucci G, Haubrich R, et al. Antibody-dependent cellular cytotoxicity independently predicts survival in severely immunocompromised human immunodeficiency virus-infected patients. J Infect Dis 1999;180:1338-41.
25. Gaardbo JC, Hartling HJ, Gerstoft J, et al. Incomplete immune recovery in HIV infection: mechanisms, relevance for clinical care, and possible solutions. Clin Dev Immunol 2012;2012:670957.
26. Giagulli C, Marsico S, Magiera AK, et al. Opposite effects of HIV-1 p17 variants on PTEN activation and cell growth in B cells. PLoS One 2011;6:e17831.
27. Glennie MJ, French RR, Cragg MS, et al. Mechanisms of killing by anti-CD20 monoclonal antibodies. Mol Immunol 2007;44:3823-37.
28. Goedert JJ, Coté TR, Virgo P, et al. Spectrum of AIDS-associated malignant disorders. Lancet 1998;351:1833-9.
29. Gonzalez-Hernandez MJ, Cavalcoli JD, Sartor MA, et al. Regulation of the human endogenous retrovirus K (HML-2) transcriptome by the HIV-1 Tat protein. J Virol 2014;88:8924-35.
30. Gopal S, Patel MR, Yanik EL, et al. Temporal trends in presentation and survival for HIV-associated lymphoma in the antiretroviral therapy era. J Natl Cancer I 2013;105:1221-9.
31. Haas A, Zimmermann K, Oxenius A. Antigen-dependent and-independent mechanisms of T and B cell hyperactivation during chronic HIV-1 infection. J Virol 2011;85:12102-13.
32. He B, Qiao X, Klasse PJ, et al. HIV-1 envelope triggers polyclonal Ig class switch recombination through a CD40-independent mechanism involving BAFF and C-type lectin receptors. J Immunol 2006;176:3931-41.
33. Hleyhel M, Belot A, Bouvier AM, et al. Risk of AIDS-defining cancers among HIV-1-infected patients in France between 1992 and 2009: results fromthe FHDH-ANRS CO4 cohort. Clin Infect Dis 2013;57:1638-47.
34. Hleyhel M, Bouvier AM, Belot A, et al. Risk of non-AIDS-defining cancers among HIV-1-infected individuals in France between 1997 and 2009: results from a French cohort. AIDS 2014;28:2109-18.
35. Hu PF, Hultin LE, Hultin P, et al. Natural killer cell immunodeficiency in HIV disease is manifest by profoundly decreased numbers of CD16+CD56+ cells and expansion of a population of CD16dimCD56-cells with low lytic activity. J Acq Immun Def Synd 1995;10:331-40.
36. Isgro A, Leti W, De Santis W, et al. Altered clonogenic capability and stromal cell function characterize bone marrow of HIV-infected subjects with low CD4+ T cell counts despite viral suppression during HAART. Clin Infect Dis 2008;46: 1902-10.
37. Kariya R, Taura M, Suzu S, et al. HIV protease inhibitor Lopinavir induces apoptosis of primary effusion lymphoma cells via suppression of NF-kappaB pathway. Cancer Lett 2014;342: 52-9.
38. Kloss M, Decker P, Baltz KM, et al. Interaction of monocytes with NK cells upon toll-like receptor-induced expression of the NKG2D ligand MICA. J Immunol 2008;181:6711-9.
39. Kowalkowski MA, Mims MA, Day RS, et al. Longer duration of combination antiretroviral therapy reduces the risk of Hodgkin lymphoma: a cohort study of HIV-infected male veterans. Cancer Epidemiol 2014;38:386-92.
40. Kundu RK, Sangiorgi F, Wu LY, et al. Expression of the human immunodeficiency virus-Tat gene in lymphoid tissues of transgenic mice is associated with B-cell lymphoma. Blood 1999;94:275-82.
41. Kuri-Cervantes L, de Oca GS, Avila-Ríos S, et al. Activation of NK cells is associated with HIV-1 disease progression. J Leukocyte Biol 2014;96:7-16.
42. Lapadula G, Cozzi-Lepri A, Marchetti G, et al. Risk of clinical progression among patients with immunological nonresponse despite virological suppression after combination antiretroviral treatment. AIDS 2013;27:769-79.
43. Lee JH, Kim Y, Choi JW, et al. Prevalence and prognostic significance of Epstein-Barr virus infection in classical Hodgkin's lymphoma: a meta-analysis. Arch Med Res 2014;45:417-31.
44. Lefevre EA, Krzysiek R, Loret EP, et al. Cutting edge: HIV-1 Tat protein differentially modulates the B cell response of naive, memory, and germinal center B cells. J Immunol 1999;163:1119-22.
45. Lichtfuss GF, Cheng WJ, Farsakoglu Y, et al. Virologically suppressed HIV patients show activation of NK cells and persistent innate immune activation. J Immunol 2012;189:1491-9.
46. Lindqvist M, van Lunzen J, Soghoian DZ, et al. Expansion of HIVspecific T follicular helper cells in chronic HIV infection. J Clin Invest 2012;122:3271-80.
47. Liu J, Hamrouni A, Wolowiec D, et al. Plasma cells from multiplemyeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-gamma and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway. Blood 2007;110:296-304.
48. Liu Q, Sun Y, Rihn S, et al. Matrix metalloprotease inhibitors restore impaired NK cell-mediated antibody-dependent cellular cytotoxicity in human immunodeficiency virus type 1 infection. J Virol 2009;83:8705-12.
49. Luteijn R, Sciaranghella G, van Lunzen J, et al. Early viral replication in lymph nodes provides HIV with a means by which to escape NK-cell-mediated control. Eur J Immunol 2011;41:2729-40.
50. Luzzi A, Morettini F, Gazaneo S, et al. HIV-1 Tat induces DNMT over-expression through microRNA dysregulation in HIV-related non Hodgkin lymphomas. Infect Agent Cancer 2014;9:41.
51. Martin G, Roy J, Barat C, et al. Human immunodeficiency virus type 1-associated CD40 ligand transactivates B lymphocytes and promotes infection of CD4+ T cells. J Virol 2007;81: 5872-81.
52. Mavilio D, Benjamin J, Daucher M, et al. Natural killer cells in HIV-1 infection: dichotomous effects of viremia on inhibitory and activating receptors and their functional correlates. P Natl Acad Sci USA 2003;100:15011-6.
53. Moir S, Malaspina A, Ho J, et al. Normalization of B cell counts and subpopulations after antiretroviral therapy in chronic HIV disease. J Infect Dis 2008;197:572-9.
54. Montoto S, Shaw K, Okosun J, et al. HIV status does not influence outcome in patients with classical Hodgkin lymphoma treated with chemotherapy using doxorubicin, bleomycin, vinblastine, and dacarbazine in the highly active antiretroviral therapy era. J Clin Oncol 2012;30:4111-6.
55. Moses A, Nelson J, Bagby GC, Jr. The influence of human immunodeficiency virus-1 on hematopoiesis. Blood 1998;91:1479-95.
56. Muller F, Tjønnfjord GE, Nordøy I, et al. Immunophenotypic analyses of CD34(+) cell subsets in bone marrow from HIVinfected patients during highly-active antiretroviral therapy. Eur J Clin Invest 2002;32:535-40.
57. Patel P, Hanson DL, Sullivan PS, et al. Incidence of types of cancer among HIV-infected persons compared with the general population in the United States, 1992-2003. Ann Intern Med 2008;148:728-36.
58. Perreau M, Savoye AL, De Crignis E, et al. Follicular helper T cells serve as the major CD4 T cell compartment for HIV-1 infection, replication, and production. J Exp Med 2013;210: 143-56.
59. Polesel J, Clifford GM, Rickenbach M, et al. Non-Hodgkin lymphoma incidence in the Swiss HIV Cohort Study before and after highly active antiretroviral therapy. AIDS 2008;22: 301-6.
60. Popovic M, Tenner-Racz K, Pelser C, et al. Persistence of HIV-1 structural proteins and glycoproteins in lymph nodes of patients under highly active antiretroviral therapy. P Natl Acad Sci USA 2005;102:14807-12.
61. Regidor DL, Detels R, Breen EC, et al. Effect of highly active antiretroviral therapy on biomarkers of B-lymphocyte activation and inflammation. AIDS 2011;25:303-14.
62. Rosignoli G, Cranage A, Burton C, et al. Expression of PD-L1, a marker of disease status, is not reduced by HAART in aviraemic patients. AIDS 2007;21:1379-81.
63. Sangaletti S, Tripodo C, Portararo P, et al. Stromal niche communalities underscore the contribution of the matricellular protein SPARC to B-cell development and lymphoid malignancies. Oncoimmunology 2014;3:e28989.
64. Sauce D, Larsen M, Fastenackels S, et al. HIV disease progression despite suppression of viral replication is associated with exhaustion of lymphopoiesis. Blood 2011;117:5142-51.
65. Sennepin A, Baychelier F, Guihot A, et al. NKp44L expression on CD4+ T cells is associated with impaired immunological recovery in HIV-infected patients under highly active antiretroviral therapy. Aids 2013;27:1857-66.
66. Sloand EM, Maciejewski J, Kumar P, et al. Protease inhibitors stimulate hematopoiesis and decrease apoptosis and ICE expression in CD34(+) cells. Blood 2000;96:2735-9.
67. Taub DD, Sayers TJ, Carter CR, et al. Alpha and beta chemokines induce NK cell migration and enhance NK-mediated cytolysis. J Immunol 1995;155:3877-88.
68. Thompson LD, Fisher SI, Chu WS, et al. HIV-associated Hodgkin lymphoma: a clinicopathologic and immunophenotypic study of 45 cases. Am J Clin Pathol 2004;121:727-38.
69. Titanji K, Chiodi F, Bellocco R, et al. Primary HIV-1 infection sets the stage for important B lymphocyte dysfunctions. AIDS 2005;19:1947-55.
70. Van Epps P, Matining RM, Tassiopoulos K, et al. Older age is associated with peripheral blood expansion of naive B cells in HIV-infected subjects on antiretroviral therapy. PLoS One 2014;9:e107064.
71. Vendrame E, Hussain SK, Breen EC, et al. Serum levels of cytokines and biomarkers for inflammation and immune activation, and HIV-associated non-Hodgkin B-cell lymphoma risk. Cancer Epidem Biomar 2014;23:343-9.
72. White MK, Pagano JS, Khalili K. Viruses and human cancers: a long road of discovery of molecular paradigms. Clin Microbiol Rev 2014;27:463-81.
73. Wilson EM, Sereti I. Immune restoration after antiretroviral therapy: the pitfalls of hasty or incomplete repairs. Immunol Rev 2013;254:343-54.
74. Zhou Q, Gil-Krzewska A, Peruzzi G, et al. Matrix metalloproteinases inhibition promotes the polyfunctionality of human natural killer cells in therapeutic antibody-based anti-tumour immunotherapy. Clin Exp Immunol 2013;173: 131-9.